Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].
Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
Hospital Universitário Evangelico de Curitiba, Curitiba, Parana, Brazil
University of Cincinnati, Dept. of Emergency Medicine, Cincinnati, Ohio, United States
Rainbow Babies and Children's Hospital, Univeristy Hospitals Case Medical Center, Cleveland, Ohio, United States
Research Site, Odesa, Ukraine
William Beaumont Hospital, Royal Oak, Michigan, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.